相关实验视频
Updated: Jul 10, 2026

09:14
Tracking Hypoxic Signaling within Encapsulated Cell Aggregates
Published on: December 16, 2011
10.7K
一个持续氧化的大型封装系统使得胰岛素分泌细胞的高密度包装和输送成为可能
Tung T Pham1, Phuong L Tran1, Linda A Tempelman2
1Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, USA.
Nature communications
|August 11, 2025
概括
这项研究引入了一种新的产生氧气的植入物,用于封装胰岛素细胞,这对于治疗1型糖尿病至关重要. 该系统通过确保为细胞生存和功能提供足够的氧气,成功地逆转了大鼠的糖尿病.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 糖尿病研究 糖尿病研究
背景情况:
- 封装胰岛素分泌细胞是1型糖尿病的潜在治疗方法,但有限的氧气阻碍了细胞的生存和可扩展性.
- 细胞封装系统中的缺氧是临床转化的一个重要障碍.
研究的目的:
- 开发和评估一个具有集成氧气发生器的新型封装平台,以改善基于细胞的糖尿病治疗.
- 评估持续氧气供应对封装细胞活力,功能和体内治疗结果的有效性.
主要方法:
- 开发了一个平台,将小型植入式电化学氧气发生器 (iEOG) 与可扩展的细胞袋结合起来.
- 利用组织水分的电解来持续产生氧气.
- 在低氧条件下和1型糖尿病的全基性大鼠模型中评估了体外系统的性能.
主要成果:
- 该iEOG系统提供稳定,可控制的氧气,在低氧条件下保持细胞活力和功能.
- 实现了高密度细胞封装 (6万IEQ/mL).
- 氧化系统的皮下植入可以在没有免疫抑制的情况下在老鼠中逆转糖尿病,长达三个月.
结论:
- 通过可植入装置持续氧化对于功能性,高密度岛屿封装是可行的.
- 这种方法克服了缺氧的局限性,推进了1型糖尿病的基于细胞的治疗方法.
- 开发的平台显示出对最小侵入性,临床可转化糖尿病治疗的承诺.
相关概念视频
Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

